Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose XXXX and @entity1199 -activated killer cells.

@entity1 @entity137 @entity270 @entity5 @entity620 @entity294 @entity391 @entity591 @entity551 @entity1358 @entity1199 @entity694 @entity221 @entity320 @entity9050
Adoptive immunotherapy of @entity1 @entity5 was investigated in our institution as part of a National @entity5 Institute extramural group study. This treatment, for @entity1 with metastatic @entity320 , @entity1358 , and @entity694 , consisted of three phases: (a) 5 days of i.v. high-dose (10(5) units/kg every 8 h) @entity1199 , (b) 6 1/2 days of rest plus leukapheresis; and (c) 4 days of high-dose @entity1199 plus three infusions of autologous @entity1199 -activated killer cells. @entity137 included @entity221 , chills, @entity591 , @entity551 , @entity391 , @entity294 , and fluid retention. @entity620 is known to be important to cell-mediated immunity, and it has been reported to be depleted during physiologically stressful events. Therefore, we determined plasma @entity620 levels in @entity1 (n = 11) before adoptive immunotherapy and before and after Phases 1, 2, and 3 of treatment. @entity1 entering the trial were not malnourished. Mean plasma @entity620 levels were normal (0.64 +/- 0.25 mg/dl) before therapy. Mean levels dropped by 80% after the first phase of treatment with high-dose @entity1199 alone (0.13 +/- 0.08 mg/dl). Mean plasma @entity620 levels remained severely depleted (0.08 to 0.13 mg/dl) throughout the remainder of the treatment, becoming undetectable (less than 0.05 mg/dl) in eight of 11 @entity1 during this time. Values obtained from 24-h urine collections on two of two @entity1 indicated that @entity9050 was not excreted in the urine. Plasma @entity620 normalized in three of three @entity1 tested 1 mo after the completion of treatment. Unlike the results for @entity620 , blood pantothenate and plasma @entity270 remained within normal limits in all 11 @entity1 throughout the phases of therapy. Responders (n = 3) differed from nonresponders (n = 8) in that plasma @entity9050 levels in the former recovered to at least 0.1 mg/dl (frank clinical scurvy) during Phases 2 and 3, whereas levels in the latter fell below this level.
